Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13522226 | 0.88 | PDE4A (0.33) | KDM4ENPC1ALOX15TSHRRAB9A | |
| SCHEMBL8243106 | 0.84 | HSP90AA1 (0.31) | KDM4ENPC1ALOX15TSHRRAB9A | |
| SCHEMBL6401815 | 0.78 | PDE4A (0.33) | KDM4ENPC1ALOX15TSHRRAB9A | |
| SCHEMBL2116132 | 0.78 | — | — | |
| SCHEMBL10703268 | 0.76 | — | — | |
| SCHEMBL6033472 | 0.75 | PDE10A (0.44) | KDM4ENPC1ALOX15TSHRRAB9A | |
| SCHEMBL20595698 | 0.72 | PDE4A (0.34) | TSHRLMNA | |
| SCHEMBL19917169 | 0.71 | GAA (0.30) | — | |
| SCHEMBL28030882 | 0.70 | PIK3CD (0.34) | HTTKDM4ENPC1ALOX15TSHR | |
| SCHEMBL10744210 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379555-B1 | PURINE COMPOUNDS | LILLY CO ELI (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8252798-B2 | Purine compounds | ELI LILLY AND COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| WO-2011058478-A1 | SUBSTITUTED TRIAZOLOPYRIMIDINES AS PDE8 INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058478-A1 | SUBSTITUTED TRIAZOLOPYRIMIDINES AS PDE8 INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20100160288-A1 | Purine Compounds | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100010020-A1 | PHOSPHODIESTERASE 4 INHIBITORS | LIU RUIPING | 2010-01-14 | — | — | US | disclosed |
| US-20100010020-A1 | PHOSPHODIESTERASE 4 INHIBITORS | LIU RUIPING | 2010-01-14 | — | — | US | disclosed |
| US-20100004236-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TEHIM ASHOK | 2010-01-07 | — | — | US | disclosed |
| US-20100004236-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TEHIM ASHOK | 2010-01-07 | — | — | US | disclosed |
| US-20090325982-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2009-12-31 | — | — | US | disclosed |
| US-7342021-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342021-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7335654-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335654-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-02-26 | — | — | US | disclosed |
| US-7332486-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332486-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2004-05-27 | — | — | US | disclosed |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3B, PDE3A | MEN1 2172/4885HTT 4634/4885KMT2A 2478/4885 |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | MEN1 1764/4885HTT 4684/4885KMT2A 2803/4885 |
| US-20100160288-A1 | Purine Compounds | P2RX1, P2RX7, P2RX5 | MEN1 4244/4885HTT 3462/4885KMT2A 3328/4885 |
| US-20100004236-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | MEN1 2172/4885HTT 4634/4885KMT2A 2478/4885 |
| US-20090325982-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | MEN1 2172/4885HTT 4634/4885KMT2A 2478/4885 |
| US-20100010020-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | MEN1 2172/4885HTT 4634/4885KMT2A 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.